Research programme: ubiquitin-specific protease inhibitors - Almac Discovery/Genentech
Latest Information Update: 01 Apr 2016
At a glance
- Originator Almac Discovery
- Developer Almac Discovery; Genentech
- Class Small molecules
- Mechanism of Action Endopeptidase inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Research Cancer
Most Recent Events
- 15 Jun 2015 Early research in Cancer in United Kingdom (unspecified route)